Lunai Bioworks Inc. · NASDAQ:LNAI
Lunai Bioworks — Investor Presentation (January 2026)
27 slides from Lunai Bioworks's investor presentation, January 2026
Slide 1: Investor Overview
Decoding life. Discovering cures. INVESTOR OVERVIEW January 2026, NASDAQ: LNAI
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements This presentation has been prepared by Lunai Bioworks, Inc. (“Lunai” or the “Company”) for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. This presentation contains forward-looking st
Slide 3: Lunai Bioworks is a next-generation drug discovery platform company
Lunai Bioworks is a next-generation drug discovery platform company that de-risks therapeutics before they reach the clinic • Our Augusta platform applies advanced AI to deeply characterize patient populations in complex disorders. • We then validate potential therapeutics in living systems, produci
Slide 4: Biology is complex. The problem isn't lack of investment, it's lack of biological resolution
Biology is complex. The problem isn’t lack of investment, it’s lack of biological resolution. >90% Despite trillions invested, most therapies for complex diseases manage symptoms rather than cure disease, because they assume a single biology where none exists. of clinical trials fail, most Lunai ide
Slide 5: An estimated 26% of Americans suffer from a diagnosable neurological disorder
An estimated 26% of Americans suffer from a diagnosable neurological disorder. Parkinson’s Disease1 U.S. 1.1 million patients Worldwide >10 million patients Annual drug sales $7-7.5B Epilepsy2 U.S. 3.5 million patients Worldwide 50 million patients Annual drug sales $10-11B Mental health3 U.S. 60 mi
Slide 6: The growing unmet need in pharma
The growing unmet need in pharma The market imperative The biopharma industry is deploying massive capital into external innovation to address a looming ($240B) patent cliff. The strategic focus has shifted to de-risking biology before clinical investment The strategic gap Pharma’s current AI invest
Slide 7: The market has shifted. AI investments are moving upstream
The market has shifted. AI investments are moving upstream. DISCOVERY Early AI investments focused on chemistry optimization and molecular design. Today, the Target ID & NEW STRATEGIC strategic priority has shifted to “biology-first” Validation AI INVESTMENT platforms that can: FOCUS • Integrate hig
Slide 8: The next generation of AI drug discovery for neurology is Phenomics-driven
The next generation of AI drug discovery for neurology is Phenomics-driven. Biology is complex and so is the data. We take a patient-centric approach that uses machine learning to : o assign phenotypes to clinical data o add genomics data to predictions o integrate high-content, in vivo experimentat
Slide 9: Why Phenomics?
Why Phenomics? Phenomics is an emerging field of research that leverages AI/ML predictions from human clinical, genomic and transcriptomic data, to direct and de-risk phenotypic screens that embrace complex biology and improve clinical translation. 2x 62% Clinical trial success Of First-in-Class NCE
Slide 10: The Augusta Platform – AI meets phenomics
The Augusta Platform – AI meets phenomics CLINICAL INSIGHTS Patented AI process to group patients based on phenotype, identify biomarkers, and prioritize therapeutic targets. Hundreds of proprietary models used to map PHENOGRAPH Phenotypes from the clinic to the experimental lab. AUGUSTA Quantifying
Slide 11: Patient dataset analysis identifying disease sub-groups, targets, biomarkers
Patient dataset analysis identifying C LI N I C AL IN S I GH T S disease sub-groups, therapeutic targets, biomarkers, and drug responses Output: PATIENT CLINICAL BIOMARKERS GENOMICS • Biomarker identification for monitoring trial success • Grouping of patients based on medical records, genomics, or
Slide 12: Augusta identifies sub-type specific biomarkers in Parkinson's Disease
Augusta identifies sub-type specific biomarkers in Parkinson’ Disease
Slide 13: Identifying clinical biomarkers to improve diagnosis in COVID-ARDS
Improving ARDS diagnosis - Feature Combination PA R TN E R S H IP Identifying clinical biomarkers to Improve diagnosis in COVID-ARDS Acute Respiratory Distress Syndrome (ARDS) is the COVID-ARDS phenoclustering leading cause of death in COVID-19 patients. ARDS trials have high failure rates, likely d
Slide 14: Combination of clinical and proteomic data find novel biomarkers
PA R TN E R S H IP Combination of clinical and Probes were proteomic data find novel associated to multiple clinical biomarkers of disease progression measurements Learning procedure using two distinct clinical sites • Built a univariate model for each of nearly 2000 proteomic probes with/without st
Slide 15: Phenograph
Phenograph The Phenograph enables quick translation between human clinical and model system phenotypes. It applies our patented ContingentAI process to fill in the whitespace of known gene-phenotype associations using machine learning. 77% 329 Of data is proprietary Gene-disease and AI-derived prior
Slide 16: Deerfield partnership to discover and develop novel therapeutics
Deerfield partnership to discover and develop novel therapeutics ✓ Deerfield is an investment management firm and their 3DC group is an internal R&D organization that progresses novel therapeutic targets with a goal of out-licensing therapeutic assets to pharma companies at the preclinical or clinic
Slide 17: Computer vision
Computer vision Speed to validation Zebrafish offer whole organism vertebrate biology, where genetic predictions are rapidly validated in vivo on our automated high-throughput platform. Combined with our proprietary Computer Vision software, speed to target validation and Hit ID can be achieved in w
Slide 18: Seizure assay results in zebrafish genetic models
✓ Captured multi-dimensional morphological & behavioral phenotypes PA R TE R N S H IP ✓ Quantified effect Car of small molecule drug to reduce seizure phenotype in genetic models and predict patient responses Seizure Assay 0.07 0.06 PREDICTED ZEBRAFISH PH ENOTYPE Activity (% change) 0.05 GENES GENET
Slide 19: Accelerating drug discovery timelines with AI-enabled, high-content analysis
Accelerating drug discovery timelines with AI-enabled, high-content analysis P H E N O G R A P H TM PHENOMIC A SSA YS COMPUTER VISION Translation between human Gene disruption and observation Quantification of responses, clinical and model system of behavioral and morphological hit detection and phe
Slide 20: NIH STTR grant allows for increased experimental capacity
NIH STTR grant allows for increased experimental capacity BioSymetrics (a subsidiary of Lunai Bioworks) received a fast-tracked Phase I/II STTR grant in August 2025 to identify novel therapeutics for Alcohol Use Disorder (AUD) using its AI-based zebrafish platform. This $1.85M grant, shared with Bri
Slide 21: AI-enabled behavioural measurements allow advanced neurological validation at scale
AI-enabled behavioural measurements allow advanced neurological validation at scale • We have developed a suite of motion parameters to interrogate multiple aspects of neurological function, including: Gross motion, Spatial exploration (well coverage and behavioral patterns related to anxiety), Micr
Slide 22: The Augusta Platform - Validation
The Augusta Platform - Validation CLINICAL INSIGHTS PHENOGRAPH AUGUSTA COMPUTER VISION CONTINGENT AI the patented core technology that deploys machine learning through automated pre-processing MOA MINER pipelines of thousands of models
Slide 23: The $170B patent cliff driving urgent deal-making
The $170B patent cliff driving urgent deal-making Scale and urgency of the crisis $170B+ 70 90%+ Revenue at Risk Blockbuster Drugs Price Compression Annual pharmaceutical revenue facing Number of blockbuster products (each Typical revenue decline post-loss of generic competition by 2030, representin
Slide 24: Why we fit pharma's LOE needs
Why we fit pharma's LOE needs We are uniquely positioned to address pharmaceutical companies' patent cliff challenges in neuroscience. Our combination of de-risked clinical assets, clean intellectual property, precision medicine approach, and focus on underserved indications directly addresses the s
Slide 25: What we offer: AI-driven patient stratification, biomarker discovery, disease subtyping
What we offer: AI-driven patient stratification, biomarker discovery, disease subtyping, and asset development Delivering actionable insights from real-world and clinical data to accelerate therapeutic development. Patient Subtyping & Disease Stratification Biomarker Discovery & Trial Enrichment In
Slide 26: Lunai is unique in the precision medicine and drug discovery space
Lunai is unique in the precision medicine and drug discovery space We have a unique platform for data standardization and integration and are the only tech bio company that couples sophisticated AI predictions with scalable validation in living organisms. Experiments are efficiently driven through A
Slide 27: Deal Pipeline Timeline and Expected Closures (2026)
Deal Pipeline Timeline and Expected Closures (2026) Q1 2026 Q2 2026 Q3-Q4 2026 Target: 1-2 signed deals. Target: 3-4 additional Target: 6-8 total deals for deals. year. Deal Size Expectations • Targeting at least one multi-million-dollar deal via expansion. • Strategy prioritizes repeatable medium-s
Lunai Bioworks — Investor Presentation (January 2026) on 6ix